Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. Its lead products candidate includes avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Amylyx Pharmaceuticals, Inc.

LifeSci Capital analyst Rami Katkhuda maintained a Buy rating on Amylyx Pharmaceuticals Inc today and set a price target of $44.00. Katkhuda covers...

Amylyx Pharmaceuticals Inc (AMLX) Gets a Buy from LifeSci Capital

Amylyx Pharmaceuticals Inc ( ($AMLX) ) just unveiled an announcement. On August 19, 2026, Amylyx Pharmaceuticals Inc. entered into an underwriting ...

Amylyx Pharmaceuticals Announces Equity Offering to Fund Avexitide

According to a report in the Wall Street Journal, Costco ($COST) is about to launch its own Medicare Advantage plan in two states as part of a limi...

Costco’s Healthcare Move Turns Heads. We’re Buying These Pharma Stocks Instead.

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amylyx Pharmaceuticals Inc (AMLX), Moderna (MRNA) ...

Analysts Conflicted on These Healthcare Names: Amylyx Pharmaceuticals Inc (AMLX), Moderna (MRNA) and Merck & Company (MRK)

Amylyx Pharmaceuticals ($AMLX) stock jumped 45% to $28.38 in early trading on Tuesday, August 18, after the company reported positive results from ...

Amylyx Shares Jump 45% Following Positive Phase 3 Trial Results for GLP-1 Blocker Avexitide

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Amylyx Pharmaceuticals Inc (AMLX) and BioMarin Pharm...

Analysts’ Top Healthcare Picks: Amylyx Pharmaceuticals Inc (AMLX), BioMarin Pharmaceutical (BMRN)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Amylyx Pharmaceuticals Inc (AMLX), Insight Molecular...

Analysts Offer Insights on Healthcare Companies: Amylyx Pharmaceuticals Inc (AMLX), Insight Molecular Diagnostics (IMDX) and Innovent Biologics (OtherIVBXF)

	A	B	C	D
1	Symbol	Price	Change	Volume
2	AMLX	$34.74	-6.56%	1.36M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	AMLX	$34.74	-6.6%	1.36M
3
4
5
6

AMLX

Get Amylyx Pharmaceuticals, Inc. Data in Excel

Get Amylyx Pharmaceuticals, Inc. Data in Excel